



GENFIT accelerates its growth and strengthens its management team both in France and the U.S.

Jean-Louis Junien, Ph.D., formerly CSO of Fournier Pharma (Solvay Group) is appointed as Executive Scientific Advisor of the company and Kia Motesharei, Ph.D. as Vice President of Business Development with Genfit Corp.

Lille (France), Cambridge (Massachusetts, USA), September 13, 2007 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company committed to drug discovery and development in the field of cardiovascular, inflammatory, and metabolic disease today announced the appointments of Dr. Jean-Louis Junien as Executive Scientific Advisor of the Company and Dr. Kia Motesharei as Vice President of Business Development with Genfit Corp., located in Cambridge, Massachusetts.

Jean-François Mouney, Chairman and CEO of Genfit declared: “It’s a great honor and a fantastic opportunity for us to welcome Jean-Louis Junien and Kia Motesharei. Their experiences and their acumen are strong assets for the company. Dr. Junien, formerly CSO of Fournier Pharma -Solvay Group- has considerable experience both in Europe and in the US in managing preclinical and clinical developments. For his part, Dr. Motesharei’s appointment will strengthen our role in the US bringing us substantial expertise in deal negotiations with big pharma and biotech companies. We are very proud to welcome them at the time when Genfit is focused on establishing new partnerships and alliances with pharmaceutical and biotech companies, especially in the US, and creating added value to our proprietary pipeline of drug candidates.”

Dr. Junien’s previous management career includes long experience in pharmaceutical industry. His most recent position was Chief Scientific Officer (CSO) of Fournier Pharma a member of the Solvay group. He was previously Chief Scientific Officer of Ferring Pharmaceuticals, a Scandinavian based company after being the Research Director of the Ferring Research Institutes in Southampton (UK) and La Jolla (US). From 1982 to 1992 he was Vice president Research & Development at Jouveinal laboratories, and then Vice President Research & Development Jouveinal - Warner-Lambert (1992-1995). Jean-Louis Junien has a Doctorate degree in pharmacy and holds postgraduate degrees in biology and pharmacology from the University and Medical School of Paris.

Expert in the field of nuclear receptors, he is a member of the scientific board of the LEEM (French equivalent of PhRMA). Jean-Louis Junien received the Galien Price for its research on opioids in 1992.

Dr. Jean-Louis Junien said: “Genfit impressed me for several reasons. On the scientific level, the thorough knowledge of its teams, whose biological approach is firmly anchored in the genomic and the proteomic, constitutes a major competing advantage. On the industrial side, the Company’s business model simultaneously based on partnerships agreements with the largest players of pharmaceutical industry and a robust pipeline of innovative proprietary products appeared extremely attractive to me. I’m looking forward to take part in the future successes of Genfit’s drug candidates.”

Dr. Kia Motesharei is a former biotech executive with over 10 years of experience in pharmaceutical and biotechnology industry. Prior to joining Genfit Corp., he founded BTeK Consulting, a specialized consulting firm focusing in business development, licensing, and new venture efforts for life science industry. Previously, Dr. Motesharei was Vice President of Corporate Development at ActivX Biosciences, Inc., a venture capital backed biopharmaceutical company focusing on discovery and development of drugs in the areas of neutropenia and diabetes, as well as, proteomics technology development. Before ActivX, he was Director of Business Development at LION bioscience, Inc. (Nasdaq: LEON) focusing on LION’s cardiovascular programs. Dr. Motesharei started his career at Trega Biosciences (Nasdaq: TRGA) as New Technologies Manager. Dr. Motesharei received his B.A. in Chemistry from The Colorado College and his Ph.D. in Organic Chemistry from University of California, Los Angeles. He spent two years at The Scripps Research Institute as an NIH postdoctoral fellow. His scientific work has been published extensively in the *Journal of American Chemical Society* and *Science*.

About GENFIT

An emerging biopharmaceutical company, GENFIT studies the deregulation of genes implicated in the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with industrial pharmaceutical companies such as SANOFI-AVENTIS, PIERRE FABRE, FOURNIER (SOLVAY Group), MERCK AG, SERVIER, deal with the most prevalent metabolic and inflammatory diseases. GENFIT's internal drug discovery and development focuses on global cardiometabolic risks, attacking several pathologies (atherosclerosis, diabetes, obesity, etc.) simultaneously, using a multimodal approach to identify single molecules addressing multiples indications.

GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development, carried out by GENFIT alone or in partnership. Four molecules are in Phase II: 2 proprietary products and 2 molecules in partnership with Sanofi-Aventis (AVE8134 and AVE0847). In addition, another molecule in partnership with Sanofi-Aventis (AVE0897) is completing Phase I.

With facilities in Lille, France, and Cambridge (USA), the Company was founded by Jean-François MOUNEY, Chairman of the Management Board, with the scientific support of Jean-Charles FRUCHART, Chairman of the Supervisory Board. As of September of 2007, its staff was comprised of 130 employees, including more than 100 scientists. Genfit is a public company listed on the Alternext of EuronextTM Paris. (www.genfit.com).

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board
+ 33 (0)3 20 16 40 00

Milestones – Press Relations

Bruno Arabian
+ 33 (0)1 70 08 04 13/+ 33 (0)6 87 88 47 26
milestones@milestones-fr.com

Warning: This press release expressly contains, in an implicit manner, certain prospective statements concerning GENFIT and its activity. These statements rely on certain risks, known or unknown, uncertainty or on other factors that may lead to actual results, financial conditions, performance or achievements on the part of GENFIT that may differ significantly from the results, financial conditions, performance or achievements expressed or implied in these prospective statements. GENFIT is issuing this press release on the present date and is not committed to update the prospective statements contained therein, either as a result of new information, future events or other. For a description of the risks or uncertainty of a nature to cause a difference between GENFIT's actual results, financial conditions, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" on the Prospectus available on the GENFIT website: <http://www.genfit.com>